Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs BIO-TECHNE Corp — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $149.73 (market cap $25.25B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Direxion Daily Semiconductor Bull 3X Shares is far larger — about 2.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bull 3X Shares for 15 Days and BIO-TECHNE Corp for 63 Days on average.
| SOXL | TECH | |
|---|---|---|
Market Cap | $25.25B | $11.36B |
Volume | 50,470,974 | 5,390,331 |
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $72.61 |
52-Week Low | $30.81 | $43.31 |
Typical Hold Time | 15 Days | 63 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL trades at $158.91, down 3.26% on the day, as semiconductor volatility persists. Technical indicators show a bullish moving average signal but overbought RSI readings. Recent news highlights mixed sentiment with chip stocks showing strength but leveraged ETF risks. The ETF faces support at $155 and resistance at $161, with institutional activity showing significant position adjustments.
Outlook remains volatile given SOXL's 3x leverage structure. Strong AI demand supports semiconductor fundamentals, but timing risks and regulatory concerns create headwinds. Investors face amplified gains or losses depending on semiconductor sector momentum, requiring careful risk management in this high-volatility instrument.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
